Literature DB >> 30354208

Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.

Amar Bahadur Singh1, Bin Dong1, Fredric B Kraemer1,2, Yanyong Xu3, Yanqiao Zhang3, Jingwen Liu1.   

Abstract

Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. Approach and Results- Administration of OCA to chow-fed mice increased mRNA and protein levels of LDLR in the liver without affecting the sterol-regulatory element binding protein pathway. Profiling of known LDLR mRNA-binding proteins demonstrated that OCA treatment did not affect expressions of mRNA degradation factors hnRNPD (heterogeneous nuclear ribonucleoprotein D) or ZFP36L1 but increased the expression of Hu antigen R (HuR) an mRNA-stabilizing factor. Furthermore, inducing effects of OCA on LDLR and HuR expression were ablated in Fxr-/- mice. To confirm the post-transcriptional mechanism, we used transgenic mice (albumin-luciferase-untranslated region) that express a human LDLR mRNA 3' untranslated region luciferase reporter gene in the liver. OCA treatment led to significant rises in hepatic bioluminescence signals, Luc-untranslated region chimeric mRNA levels, and endogenous LDLR protein abundance, which were accompanied by elevations of hepatic HuR mRNA and protein levels in OCA-treated transgenic mice. In vitro studies conducted in human primary hepatocytes and HepG2 cells demonstrated that FXR activation by OCA and other agonists elicited the same inducing effect on LDLR expression as in the liver of normolipidemic mice. Furthermore, depletion of HuR in HepG2 cells by short interfering RNA transfection abolished the inducing effect of OCA on LDLR expression. Conclusions- Our study is the first to demonstrate that FXR activation increases LDLR expression in liver tissue by a post-transcriptional regulatory mechanism involving LDLR mRNA-stabilizing factor HuR.

Entities:  

Keywords:  LDLR protein, human; RNA stability; obeticholic acid; receptors, LDL; untranslated regions

Mesh:

Substances:

Year:  2018        PMID: 30354208      PMCID: PMC6206879          DOI: 10.1161/ATVBAHA.118.311122

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  47 in total

Review 1.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

2.  Statin trials and goals of cholesterol-lowering therapy.

Authors:  S M Grundy
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

Review 3.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

4.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels.

Authors:  K F Kozarsky; M H Donahee; A Rigotti; S N Iqbal; E R Edelman; M Krieger
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

Review 5.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

Authors:  Anna C Calkin; Peter Tontonoz
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-14       Impact factor: 94.444

6.  Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte.

Authors:  Fan Chao; Wei Gong; Yingru Zheng; Yuan Li; Gang Huang; Min Gao; Jialin Li; Ramalinga Kuruba; Xiang Gao; Song Li; Fengtian He
Journal:  Atherosclerosis       Date:  2010-10-16       Impact factor: 5.162

7.  FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Authors:  Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

8.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

9.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.

Authors:  Noam Zelcer; Cynthia Hong; Rima Boyadjian; Peter Tontonoz
Journal:  Science       Date:  2009-06-11       Impact factor: 47.728

View more
  7 in total

1.  Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.

Authors:  Chuangzhen Lin; Bingqing Yu; Lixin Chen; Zhaohui Zhang; Weixiang Ye; Hui Zhong; Wenke Bai; Yuping Yang; Biao Nie
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

Review 2.  Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

Review 3.  Long noncoding RNAs-a new dimension in the molecular architecture of the bile acid/FXR pathway.

Authors:  Yonghe Ma; Jamie Harris; Ping Li; Haiming Cao
Journal:  Mol Cell Endocrinol       Date:  2021-02-01       Impact factor: 4.102

4.  Danning tablets might improve glucose and lipid metabolism in asymptomatic T2MD patients after cholecystectomy: A cohort study.

Authors:  Weijie Chen; Shengnan Zhou; Jianchun Xiao; Wei Liu; Qiang Qu; Xiaodong He
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

Review 5.  The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD.

Authors:  Ting Hong; Yiyan Chen; Xiaoying Li; Yan Lu
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

6.  FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.

Authors:  Amar B Singh; Bin Dong; Fredric B Kraemer; Jingwen Liu
Journal:  Physiol Rep       Date:  2020-03

7.  Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA.

Authors:  Hilde Sundvold
Journal:  Molecules       Date:  2020-10-01       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.